Literature DB >> 11695972

Autoreactivity against interleukin 6 as a risk factor in elderly patients with colorectal carcinoma.

R Wakuda1, C Miki, M Kusunoki.   

Abstract

HYPOTHESIS: Aging results in both decreased immunity to exogenous antigens and increased autoreactivity. We suggest that the increased autoreactivity against tumor-releasing cachectic cytokine and postsurgical hypercytokinemia are involved in the cause of increased morbidity and mortality in elderly patients with colorectal cancer. DESIGN, SETTING, AND PATIENTS: Eighty-three patients with colorectal cancer admitted to a university hospital were studied prospectively.
INTERVENTIONS: Surgical specimens of primary colorectal cancer were harvested and peripheral venous blood samples were obtained perioperatively. MAIN OUTCOME MEASURES: The tissue concentrations of interleukin (IL) 1beta and IL-6 were determined. Serial determinations of serum concentrations of IL-6, IL-6 soluble receptor, and C-reactive protein were performed. Nutritional status was assessed by the creatinine height index.
RESULTS: The tumor IL-6 content was the independent factor that influenced the creatinine height index in the elderly patients, whereas Dukes classification was the only independent factor that influenced the creatinine height index in the younger patients. The elderly patients showed an exaggerated C-reactive protein response and increased IL-6 soluble receptor consumption independent of the tumor IL-6 content and postoperative IL-6 response. This immunologic disturbance was followed by a significant (P = .03) delay in the normalization of activated neutrophils, which seemed to be associated with postoperative fatal complications in the elderly patients.
CONCLUSIONS: Autoreactivity against intrinsic IL-6 was increased and seemed to be associated with poor clinical outcomes in elderly patients. To prevent fatal complications, adequate nutritional support early in treatment and attenuation of the neutrophil-related hyperinflammatory sequence by controlling the IL-6 soluble receptor affinity should be advocated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11695972     DOI: 10.1001/archsurg.136.11.1274

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  6 in total

1.  Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer.

Authors:  Yuji Toiyama; Chikao Miki; Yasuhiro Inoue; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

2.  Evaluation of an inflammation-based score for identification of appropriate patients for comprehensive genomic profiling.

Authors:  Naomi Hayashi; Ippei Fukada; Akihiro Ohmoto; Masumi Yamazaki; Xiaofei Wang; Mari Hosonaga; Shunji Takahashi
Journal:  Discov Oncol       Date:  2022-10-19

Review 3.  Remodeling of the immunoinflammatory network system in elderly cancer patients: implications of inflamm-aging and tumor-specific hyperinflammation.

Authors:  Chikao Miki; Masato Kusunoki; Yasuhiro Inoue; Keiichi Uchida; Yasuhiko Mohri; John A C Buckels; Paul McMaster
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

4.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.

Authors:  Y Okugawa; C Miki; Y Toiyama; H Yasuda; T Yokoe; S Saigusa; J Hiro; K Tanaka; Y Inoue; M Kusunoki
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

5.  Effects of Horticultural Therapy on Asian Older Adults: A Randomized Controlled Trial.

Authors:  Kheng Siang Ted Ng; Angelia Sia; Maxel K W Ng; Crystal T Y Tan; Hui Yu Chan; Chay Hoon Tan; Iris Rawtaer; Lei Feng; Rathi Mahendran; Anis Larbi; Ee Heok Kua; Roger C M Ho
Journal:  Int J Environ Res Public Health       Date:  2018-08-09       Impact factor: 3.390

6.  Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer.

Authors:  Jie You; Gui-Qi Zhu; Linka Xie; Wen-Yue Liu; Liang Shi; Ou-Chen Wang; Zong-Hai Huang; Martin Braddock; Gui-Long Guo; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.